Search

  1. ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

    Press release

    … six adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. … field stimulus testing (FST), ocular instability (OCI), optical coherence tomography (OCT), and pupillary light … global trial to be conducted at sites in North America and Europe with significant expertise in genetic retinal disease. …

  2. ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

    Press release

    … Artur Cideciyan, Ph.D., professeur de recherche en ophtalmologie à l’Institut Scheie Eye de l’Université de … Vision Test ( BRVT) et le traitement précoce de la rétinopathie diabétique (ETDRS). À trois mois de traitement, … de 30 à 40 patients atteints d’ACL10 liée à une ou deux copies de la mutation p.Cys998X et pourrait être renouvelé en …

  5. ProQR Announces Pricing of Initial Public Offering

    Press release

    LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.

  9. ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

    Press release

    … Chief Scientific Officer Proven leader with deep worldwide ophthalmology experience, including multiple approvals … MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, scientific and research management experience, … as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global …

    Naveed Shams

  10. ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    Press release

    … PQ-110-001 Phase 1/2 trial PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) … and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients … of visual function and retinal structure through ophthalmic endpoints, such as visual acuity (BCVA), mobility …